Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Davide Musmeci"'
Autor:
Davide Musmeci, Georgios Patsos, Edwin De Pauw, Valerio Ortenzi, Gabriel Mazzucchelli, Andrei Turtoi, Vincenzo Castronovo, Cristian Scatena, Generoso Bevilacqua, Robert Kiss, Daniela Murtas, Antonio Giuseppe Naccarato
Publikováno v:
Journal of Proteome Research; Vol 11
High-grade gliomas (glioblastomas) are the most common and deadly brain tumors in adults, currently with no satisfactory treatment available. Apart from de novo glioblastoma, it is currently accepted that these malignancies mainly progress from lower
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e1f0bde25a0983b715e91009f595ef0
Autor:
Vincenzo Castronovo, Davide Musmeci, Generoso Bevilacqua, Joan Somja, Ying Hong Wang, Bruno Dumont, Andrei Turtoi, Edwin De Pauw, Philippe Delvenne
Publikováno v:
Journal of Proteome Research; Vol 10
Pancreas ductal adenocarcinoma (PDAC) remains a deadly malignancy with poor early diagnostic and no effective therapy. Although several proteomic studies have performed comparative analysis between normal and malignant tissues, there is a lack of cle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51b159057dff37d43a7cf98917515ac9
https://doi.org/10.1021/pr200527z
https://doi.org/10.1021/pr200527z
Autor:
E. De Pauw, Anne-Cécile Massart, Andrei Turtoi, Maximilien Fleron, Gabriel Mazzucchelli, Vincent Hennequière, David Waltregny, Vincenzo Castronovo, M. C. De Pauw-Gillet, Yannick Greffe, Davide Musmeci
Publikováno v:
Journal of Proteomics. 73:1986-2005
In the field of proteomics there is an apparent lack of reliable methodology for quantification of posttranslational modifications. Present study offers a novel post-digest ICPL quantification strategy directed towards characterization of phosphoryla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5614eff4c4907d05df5dfa949ee3af67
https://doi.org/10.1016/j.jprot.2010.06.003
https://doi.org/10.1016/j.jprot.2010.06.003
Autor:
Paul Clement, Vassilis Golfinopoulos, Emilie Le Rhun, Ahmed Idbaih, Alba A. Brandes, Martin Bendszus, Roger Stupp, Maaike J. Vos, Jean-Sebastien Frenel, Davide Musmeci, Julien Domont, Thierry Gorlia, Wolfgang Wick, Felix Sahm, Michael Platten, Jacoline E C Bromberg, Martin J. van den Bent, François Dubois, Michel Fabbro
Publikováno v:
Journal of Clinical Oncology. 34:2019-2019
2019Background: Both lomustine (LOM) and bevacizumab (BEV) are approved agents for recurrent or progressive glioblastoma. We aimed at evaluating the optimal treatment sequence (single agent vs sequential vscombination) of these agents in a randomized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cc370ede0b82ae2710b74d46e2344b0
https://doi.org/10.1200/jco.2016.34.15_suppl.2019
https://doi.org/10.1200/jco.2016.34.15_suppl.2019
Publikováno v:
The FASEB Journal. 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7068e719195a704882c094f9979bcc9b
https://doi.org/10.1096/fasebj.24.1_supplement.354.5
https://doi.org/10.1096/fasebj.24.1_supplement.354.5